Nab-paclitaxel and carboplatin yielded a 41 percent response rate. Toxicity of the combination is “tolerable.” CHICAGO — A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according...
Posted to
News
by
AACR News
on
Tue, Apr 3 2012
Filed under:
Filed under: Press Releases, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, non-small cell lung cancer, NSCLC, 2012 Annual Meeting, Annual Meeting, nab-paclitaxel, AACR Annual Meeting 2012, carboplatin, Dr. Gregory A. Otterson
Assay could direct treatment options for triple-negative breast cancer. Accumulations of telomere AI predicted sensitivity to therapy. PHILADELPHIA — Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin...
Posted to
News
by
AACR News
on
Thu, Mar 22 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, chemotherapy, women, journal, triple-negative breast cancer, tAI, telomeric allelic imbalance, platinum chemotherapy, cisplatin, carboplatin, Dr. Andrea Richardson